KYMERA THERAPEUTICS INC

KYMRNASDAQ

🏆 #825 by market capEarnings Nov 2US Equity

$109.62▲ $1.05 (+0.96%)

🌅 Pre-market$109.91▲ 0.26%Regular close · extended-hours price shown

1h—

24h▲ 1.0%

7d▲ 4.0%

14d▲ 4.1%

30d▼ 0.7%

1y▲ 174.9%

🏦Market Cap

$9.02B

Small Cap

📈Revenue Growth (YoY)

+134.8%

High Growth

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

86.0x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $109.04 – $111.68
52-Week Range: $36.65 – $130.05
Volume: $3.25B
Avg Volume: $2.71B
Shares Outstanding: 82.3M
Next Earnings: Sep 14, 2026

Fundamentals Snapshot

Annual Revenue: $39M
Last Q Revenue: $65M
P/E Ratio: —
P/S Ratio: 86.0x
EPS (TTM): $-3.24
Dividend Yield: —

Why Investors Own KYMR

✓High-growth profile — revenue up +52.8% YoY with expanding US Equity exposure.
✓Healthy economics — 32% gross margin and 27% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$39M▲ +52.6% YoY

Gross Margin (TTM)

32.3%▲ +4.3% YoY

Operating Income (TTM)

$8M▲ +52.6% YoY

Free Cash Flow (TTM)

$10M▲ +52.6% YoY

About KYMERA THERAPEUTICS INC

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

🦦